| Literature DB >> 29175886 |
Sophie Tiphaine Loeffert1, Elise Melloul2, Cédric Dananché1,3, Laetitia Hénaff1, Thomas Bénet1,3, Pierre Cassier4, Damien Dupont5, Jacques Guillot2, Françoise Botterel2, Martine Wallon5, Marie-Paule Gustin1,6, Philippe Vanhems1,3.
Abstract
INTRODUCTION: Monitoring fungal aerocontamination is an essential measure to prevent severe invasive aspergillosis (IA) infections in hospitals. One central block among 32 blocks of Edouard Herriot Hospital (EHH) was entirely demolished in 2015, while care activities continued in surrounding blocks. The main objective was to undertake broad environmental monitoring and clinical surveillance of IA cases to document fungal dispersion during major deconstruction work and to assess clinical risk. METHODS AND ANALYSIS: A daily environmental survey of fungal loads was conducted in eight wards located near the demolition site. Air was collected inside and outside selected wards by agar impact samplers. Daily spore concentrations were monitored continuously by volumetric samplers at a flow rate of 10 L.min-1. Daily temperature, wind direction and speed as well as relative humidity were recorded by the French meteorological station Meteociel. Aspergillus fumigatus strains stored will be genotyped by multiple-locus, variable-number, tandem-repeat analysis. Antifungal susceptibility will be assessed by E-test strips on Roswell Park Memorial Institute medium supplemented with agar. Ascertaining the adequacy of current environmental monitoring techniques in hospital is of growing importance, considering the rising impact of fungal infections and of curative antifungal costs. The present study could improve the daily management of IA risk during major deconstruction work and generate new data to ameliorate and redefine current guidelines. ETHICS AND DISSEMINATION: This study was approved by the clinical research and ethics committees of EHH. © Article author(s) (or their employer(s) unless otherwise stated in the text of the article) 2017. All rights reserved. No commercial use is permitted unless otherwise expressly granted.Entities:
Keywords: aspergillus fumigatus; azole resistance; clinical monitoring; environmental monitoring; genetic patterns; invasive aspergillosis
Mesh:
Substances:
Year: 2017 PMID: 29175886 PMCID: PMC5719317 DOI: 10.1136/bmjopen-2017-018109
Source DB: PubMed Journal: BMJ Open ISSN: 2044-6055 Impact factor: 2.692
Figure 1Location of Edouard Herriot Hospital, Lyon (France).
Figure 2Detailed map of Edouard Herriot Hospital and sampling sites of environmental monitoring.
Description of manual air sampling sites monitored at Edouard Herriot Hospital
| Medical unit | ICU | Medical unit | Medical unit | Kidney and pancreas transplantation unit | ICU | ICU | |||||||||
| Sampling | Morning | Afternoon | Morning | Afternoon | Morning | Afternoon | Morning | Afternoon | Morning | Afternoon | Morning | Afternoon | Morning | Afternoon | |
| Monday | Outdoor | Building porch | Building porch | Building porch | Building porch | – | – | – | – | – | – | – | – | – | – |
| Indoor | Room+ | Room+ | Corridor+ | Corridor+ | – | – | – | – | – | – | – | – | – | – | |
| Tuesday | Outdoor | – | – | – | – | Building porch | Building porch | – | – | – | – | Building porch | Building porch | – | – |
| Indoor | – | – | – | – | 2 Corridors | 2 Corridors | – | – | – | – | Room+ | Room+ | – | – | |
| Wednesday | Outdoor | – | – | – | – | – | – | Building porch | Building porch | Building porch | Building porch | – | – | – | – |
| Indoor | – | – | – | – | – | – | 2 Corridors | 2 Corridors | Room+ | Room+ | – | – | – | – | |
| Thursday | Outdoor | Building porch | Building porch | – | – | – | – | – | – | – | – | – | – | Building porch | Building porch |
| Indoor | Room+ | Room+ | – | – | – | – | – | – | – | – | – | – | Room+ | Room+ | |
| Friday | Outdoor | Additional sampling, if needed | |||||||||||||
ICU, intensive care unit.
MLVA primers and fluorescence dyes used in each multiplex reaction
| VNTR | Fluorochromes | Primer sequences (5’–3’) | Allele size range (bp) | ||
| Multiplex 1 | Asp 167 | F: | ATTO565- | TGAGATGGTTAACTTACGTAGCGC |
|
| Asp 330 | F: | ATTO550- | ATCTGGTCGCGAAATTCCTCT |
| |
| Asp 345 | F: | Yakima Yellow- | TCTCCAACCCTTCGGACG |
| |
| Asp 443 | F: | ATTO565- | AAGCTTCGTCTGGCGAAGAG |
| |
| Asp 446 | F: | 6-FAM- | CGATCATGTTTGCCTGAGGA |
| |
| Multiplex 2 | Asp 20 | F: | 6-FAM- | GGGAAGAGAGGAACCGATCC |
|
| Asp 165 | F: | Yakima Yellow- | TGATGGGCCGCAGTCG |
| |
| Asp 202 | F: | ATTO565- | AGGATCACTGCCCTCAACCC |
| |
| Asp 204bis | F: | ATTO565- | ATTGGGAAGAGACGGGGTAT |
| |
| Asp 252 | F: | ATTO550- | CAGATTGGAGACACGAAGCG |
| |
6-FAM, 6-carboxyfluorescein; CE, capillary electrophoresis; F, forward; MLVA, multiple-locus variable-number tandem-repeat analysis; R, reverse; VNTR, variable-number tandem repeat.
Figure 3Flow chart of protocol study.